John Theurer Cancer Center, Hackensack University Medical Center | Strategic Alliance Partners

August 19, 2015

The unprecedented, soaring price of anticancer drugs (and cancer care) is not sustainable and has truly not been addressed.

August 17, 2015

The ability to identify which mutations are likely to be "drivers" in cancer pathogenesis and to elucidate how mutated genes affect the biology of a given tumor are fundamental current challenges that might provide hope in cancer genomics in the future.

May 22, 2015

Dr. Andre Goy discusses efforts to improve "compassionate use" programs that expand access to promising drugs that are not yet approved by the FDA.

May 11, 2015

Several monoclonal antibodies with multiple myeloma cell antigen or bone marrow targets have exhibited strong antimyeloma activity and may become potential therapeutic agents.

April 15, 2015

Thanks to the focus on progress in medicine, tremendous progress has been made in oncology, as illustrated in the recent 6-hour Ken Burns and Barak Goodman television documentary on cancer.

January 21, 2015

Scott Rowley, MD, the Chief of John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.

January 14, 2015

Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche's recent acquisition of the molecular testing company Foundation Medicine.

May 14, 2014

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

April 21, 2014

Medicine is undergoing a revolution that will transform the practice of healthcare, including oncology.

April 21, 2014

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the use of novel oral anticoagulants for use in patients with hematologic malignancies.

March 26, 2014

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses emerging agents in lymphoma.

March 25, 2014

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, gives an overview of novel therapies for the treatment of patients with acute myeloid leukemia (AML).

March 25, 2014

Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center, discusses emerging trends in bone marrow and stem cell transplantation.

March 24, 2014

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the administration of carfilzomib.

August 16, 2013

Finding new ways of manipulating the body's own defenses to better combat various hematologic malignancies is yielding some interesting results and could represent a very promising new field of care for patients dealing with these disorders.

August 13, 2013

While the anti-T-cell-checkpoint approach is far from perfect, the demonstrated ability for humanity to overcome evolutionary design and break tumor cell tolerance to turn the tide against cancer is nothing less than inspiring.

June 10, 2013

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, discusses the approval of the immunomodulatory agent lenalidomide (Revlimid).

March 08, 2013

On Sunday, December 9, 2012, the Plenary Session at the 54th American Society of Hematology Annual Meeting featured several noteworthy abstracts.

February 11, 2013

It has always been our job as cancer care physicians to guide the patient, even when our guidance is not what one would like to hear.

January 09, 2013

We have come a long way from the microscope of Galileo, but questions remain in actual practice about how close we need to get to help our patients.